Timing Is Everything: How Investors Can Get It Right

Timing is everything.

If you’re like most investors, then at some point you’ve sat back in your chair, closed your eyes, and dreamed of hitting that perfect trade — the one that makes the rest of the market salivate. 

You know the kind of trade I’m talking about. They’re the ones that you pick up, then wake up one morning to see an explosive move higher, perhaps doubling your investment over a brief period of time. 

You’re in and out in a heartbeat… and then you smile knowing you pulled off a trade that most people never get to experience. 

Thing is, these trades happen more frequently than you might think. In fact, we see them here in our investment community over and over for years. 

You just have to know what to look for. 

Earlier this year, a small group of biotech investors woke up one morning with a similar kind of smile I just described. 

You see, a few months prior, a company named X4 Pharmaceuticals (NASDAQ: XFOR) received news that the U.S. Food and Drug Administration (FDA) had accepted the company’s New Drug Application for a drug it was developing called mavorixafor. This drug treats individuals 12 and older with WHIM syndrome, a rare, primary immunodeficiency. 

When we decided to pull the trigger on this trade on March 15th, you would’ve been able to scoop up shares as low as $0.85 apiece. 

Less than a week later, those same shares had catapulted as much as 75% higher!

For us, these kinds of trades have become sort of commonplace. In 2022, a year which saw the S&P 500 drop nearly 20%, our investment community did the unthinkable — we went 21 for 21 and closed every single biotech trade we made for a winner!

The difference between good and bad timing is instrumental to your portfolio’s success.

However, you can whittle down your trading success to something as simple as buy low, sell high. I know it sounds easy, but the cold, hard truth that most of the investment herd may not grasp is that you won’t double your money on every single trade; not even the mighty Warren Buffett would be so bold as to claim that much. 

But what you can do is better your odds. 

Fortunately for us, our opportunities come a little more frequent than most. Just like in the case of X4 Pharmaceuticals, our small group of elite biotech investors target those hard-hitting players in the sector that are developing the next groundbreaking treatment and therapies. 

But what’s more important is this: I don’t want to just tell you about these opportunities — I want you to see them for yourself right here.

Until next time,

Keith Kohl

Check us out on YouTube!

A true insider in the technology and energy markets, Keith’s research has helped everyday investors capitalize from the rapid adoption of new technology trends and energy transitions. Keith connects with hundreds of thousands of readers as the Managing Editor of Energy & Capital, as well as the investment director of Angel Publishing’s Energy Investor and Technology and Opportunity.

For nearly two decades, Keith has been providing in-depth coverage of the hottest investment trends before they go mainstream — from the shale oil and gas boom in the United States to the red-hot EV revolution currently underway. Keith and his readers have banked hundreds of winning trades on the 5G rollout and on key advancements in robotics and AI technology.

Keith’s keen trading acumen and investment research also extend all the way into the complex biotech sector, where he and his readers take advantage of the newest and most groundbreaking medical therapies being developed by nearly 1,000 biotech companies. His network includes hundreds of experts, from M.D.s and Ph.D.s to lab scientists grinding out the latest medical technology and treatments. You can join his vast investment community and target the most profitable biotech stocks in Keith’s Topline Trader advisory newsletter.